Rivastigmine is a parasympathomimetic or cholinergic agent for the treatment of mild to moderate dementia of the Alzheimer’s type. Rivastigmine is a cholinesterase inhibitor that inhibits both butyrylcholinesterase and acetylcholinesterase. It is grouped under the following drug class(es): Neurotransmitter agents and Psychotropic agents. Its therapeutic use is listed as central nervous system (CNS) agents. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Prometax, Erastig, Kerstipon, Somniton and Alzest. Its PubChem CID is 77991.
Rivastigmine
| CAS No | 123441-03-2 |
|---|---|
| Molecular Formula | C14H22N2O2 |
| Molecular Weight | 250.34 g/mol |
| Synonyms | [3-[(1S)-1-(dimethylamino)ethyl]phenyl] N-ethyl-N-methylcarbamate |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Rivastigmine is a parasympathomimetic or cholinergic agent for the treatment of mild to moderate dementia of the Alzheimer's type. Rivastigmine is a cholinesterase inhibitor that inhibits both butyrylcholinesterase and acetylcholinesterase.
The listed CAS number is 123441-03-2.
The listed molecular formula is C14H22N2O2.
The listed molecular weight is 250.34 g/mol.
[3-[(1S)-1-(dimethylamino)ethyl]phenyl] N-ethyl-N-methylcarbamate.
The source lists Prometax, Erastig, Kerstipon, Somniton and Alzest.